Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NO2701693T3 - - Google Patents
[go: Go Back, main page]

NO2701693T3 - - Google Patents

Info

Publication number
NO2701693T3
NO2701693T3 NO12720794A NO12720794A NO2701693T3 NO 2701693 T3 NO2701693 T3 NO 2701693T3 NO 12720794 A NO12720794 A NO 12720794A NO 12720794 A NO12720794 A NO 12720794A NO 2701693 T3 NO2701693 T3 NO 2701693T3
Authority
NO
Norway
Application number
NO12720794A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2701693T3 publication Critical patent/NO2701693T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO12720794A 2011-04-29 2012-04-27 NO2701693T3 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11003508 2011-04-29
EP12720794.2A EP2701693B1 (en) 2011-04-29 2012-04-27 Tapentadol for preventing and treating depression and anxiety
PCT/EP2012/001819 WO2012146383A1 (en) 2011-04-29 2012-04-27 Tapentadol for preventing and treating depression and anxiety

Publications (1)

Publication Number Publication Date
NO2701693T3 true NO2701693T3 (sr) 2018-01-20

Family

ID=44260882

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12720794A NO2701693T3 (sr) 2011-04-29 2012-04-27

Country Status (15)

Country Link
US (3) US20120277319A1 (sr)
EP (3) EP3656380A1 (sr)
JP (3) JP6014655B2 (sr)
CY (2) CY1119586T1 (sr)
DK (2) DK2701693T3 (sr)
ES (2) ES2788548T3 (sr)
HR (2) HRP20171570T1 (sr)
HU (2) HUE049308T2 (sr)
LT (2) LT3272343T (sr)
NO (1) NO2701693T3 (sr)
PL (2) PL3272343T3 (sr)
PT (2) PT3272343T (sr)
RS (2) RS56523B1 (sr)
SI (2) SI2701693T1 (sr)
WO (1) WO2012146383A1 (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US10292948B2 (en) * 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20090306050A1 (en) 2006-02-03 2009-12-10 Timothy Dinan Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
RS55769B1 (sr) 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
JP2011507800A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのampa受容体アンタゴニスト
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
CA2757757C (en) 2009-04-30 2017-10-24 Ulrich Jahnel Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
FR2970261B1 (fr) 2011-01-10 2013-05-03 IFP Energies Nouvelles Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive
ES2703282T3 (es) 2011-04-05 2019-03-07 Gruenenthal Gmbh Tapentadol para prevenir la cronificación del dolor

Also Published As

Publication number Publication date
SI3272343T1 (sl) 2020-06-30
RS60152B1 (sr) 2020-05-29
US20150018426A1 (en) 2015-01-15
DK3272343T3 (da) 2020-04-27
US9980927B2 (en) 2018-05-29
PL3272343T3 (pl) 2020-07-27
JP6445637B2 (ja) 2018-12-26
JP2018021053A (ja) 2018-02-08
PT3272343T (pt) 2020-04-23
SI2701693T1 (sl) 2017-11-30
HRP20171570T1 (hr) 2017-11-17
JP2017031182A (ja) 2017-02-09
HUE049308T2 (hu) 2020-09-28
EP3272343B1 (en) 2020-02-12
EP2701693A1 (en) 2014-03-05
JP2014516935A (ja) 2014-07-17
HUE034003T2 (en) 2018-02-28
WO2012146383A1 (en) 2012-11-01
HRP20200600T1 (hr) 2020-10-16
RS56523B1 (sr) 2018-02-28
DK2701693T3 (da) 2017-11-13
LT3272343T (lt) 2020-05-11
JP6014655B2 (ja) 2016-10-25
CY1119586T1 (el) 2018-03-07
EP3272343A1 (en) 2018-01-24
EP2701693B1 (en) 2017-08-23
CY1123051T1 (el) 2021-10-29
ES2646363T3 (es) 2017-12-13
EP3656380A1 (en) 2020-05-27
LT2701693T (lt) 2017-11-10
PL2701693T3 (pl) 2018-01-31
US20170196822A1 (en) 2017-07-13
ES2788548T3 (es) 2020-10-21
US20120277319A1 (en) 2012-11-01
PT2701693T (pt) 2017-11-16

Similar Documents

Publication Publication Date Title
BR112013022641A2 (sr)
BR112013031251A2 (sr)
BR112013027245A2 (sr)
BR112013024383A2 (sr)
BR112013026905A2 (sr)
BR112013023185A2 (sr)
BR112013022995A2 (sr)
BR112013017670A2 (sr)
BR112013027830A2 (sr)
BR112013026744A2 (sr)
AP3853A (sr)
BR112013023927A2 (sr)
BR112013027452A2 (sr)
BR112013028733A2 (sr)
BR112013027121A2 (sr)
BR112013031556A2 (sr)
BR112013026790A2 (sr)
BR112013024588A2 (sr)
BR112013032368A2 (sr)
BR112013032377A2 (sr)
BR112013032380A2 (sr)
BR112013027836A2 (sr)
BR112013026895A2 (sr)
BR112013018949A2 (sr)
BR112013027761A2 (sr)